The DAVIO 2 Trial: A Phase 2, Randomized, Double-Masked, Controlled Multicenter Study of EYP-1901 vs Aflibercept in Previously Treated Wet Age-Related Macular Degeneration

**Results**

**Baseline Characteristics**
- Baseline characteristics were well balanced across treatment arms.

**Primary Endpoint:** Mean Change in BCVA
- The primary endpoint was met; both doses of EYP-1901 achieved statistical non-inferiority (Figure 2A).
- BCVA in eyes without supplemental injections was similar to the overall population (Figure 2B).

**Figure 2: Mean Change in BCVA From Baseline Visit**
- **Figure 2A:** Mean change in BCVA from baseline with EYP-1901 2 mg at Week 28 (+0.9, n = 52) and Week 32 (+1.0, n = 48) vs aflibercept 2 mg q8W (+0.1, n = 46).
- **Figure 2B:** Mean change in BCVA from baseline with EYP-1901 3 mg at Week 28 (+2.4, n = 31) and Week 32 (+3.0, n = 33) vs aflibercept 2 mg q8W (+1.0, n = 41).

**Reduction in Treatment Burden**
- 64%–85% of eyes receiving EYP-1901 were supplemental injection–free up to Week 32 (Figure 4).
- There was a reduction in treatment burden of 85%–89% following EYP-1901 treatment, up to Week 32 (Figure 5).

**Safety**
- EYP-1901 was well tolerated through 32 weeks with no ocular serious adverse events (SAEs) related to EYP-1901. Four serious ocular AEs were reported in study eyes and deemed unrelated to EYP-1901.

**Conclusions**
- EYP-1901 demonstrated statistical non-inferiority to aflibercept with stable BCVA, slow anatomic control, a favorable safety profile, and durability up to 6 months in eyes with AMD.
- 26% of eyes receiving EYP-1901 remained supplemental injection–free up to 8 months, and there was an 85% mean reduction in treatment burden vs the prior 6 months.
- Most serious AEs were reported with IVT injection, and no serious ocular AEs were related to EYP-1901.
- 12-month data for DAVIO 2 will be available in the second half of 2024. EYP-1901 is also being studied in phase 3 trials in neovascular diabetic retinopathy and diabetic macular edema. A phase 3 trial that in AMD will begin in the second half of 2024.